

Provision of harm reduction interventions in European prisons: short overview of available services

L. Montanari¹, S. Mazzilli¹², A.Tarjan¹, L.Vandam^{1,} I. Hasselberg¹, W. Hall³, G. Horváth⁴, Lara

Tavoschi², T. Seyler¹, H. Stover⁵

¹European Monitoring Centre for Drugs and Drug Addiction, ²Department of Translational Research in Medicine-University of Pisa,³National Centre for Youth Substance Use-The University of Queensland, ⁴Hungarian National Foal Point, ⁵Institute of Addiction Research-University of Applied Sciences.

25 November 2022


LX Addiction Conference – Barriers in the implementation of harm reduction interventions in European prisons. From evidence to practice

No conflict of interests



Drug related interventions in prison: evidence

Scarce evidence



CHAPTER 6

Available evidence and good practice addressing drug use and related harms in prison settings

Lara Tavoschi, Linda Montanari and Dagmar Hedrich




✓ OST ✓ Test, prevention and treatment of infectious diseases



Drug and Prison in Europe

Lifetime prevalence of drug use




DDA (data) I Highcharts (chart tool) © Natural Earth




Sources: EMCDDA, FONTE data 2022; Aebi, M. F. and Tiago, M. M. (2022), Council of Europe annual penal statistics SPACE I: prison populations survey 2021, Council of Europe, Strasbourg

Lifetime prevalence of drug injecting before and during imprisonment (2010-2018)





Prevalence of HIV and HCV in PWID who are in prison in some countries (2021 or most recent)






Mortality among people in prison

Mortality inside prison

- EU 10.5 deaths (VS 1.5) suicide
- 78% of deaths are violent deaths <u>1 in 10 of those violent</u> deaths are due to


intentional or accidental drug overdose or intoxication



Mortality after prison release




EMCDDA (2021), Prison and drugs in Europe: current and future challenges, Luxembourg.



Availability of drugrelated interventionsin prison setting(n. countries/out of 29)(2019 or most recent year)


EMCDDA (2021), Prison and drugs in Europe: current and future challenges, Luxembourg.

OST introduction in the community and in prison (EU27, NO, TK)





Coverage of HIV and HCV testing in prison






EMCDDA (2021), Prison and drugs in Europe: current and future challenges, Luxembourg- HA-REACT. – UK included 10

Changes in the availability of selected harm reduction interventions: 2019 and 2021

(n. of countries- 28 countries)




| 11

Trend in the share of prison population in OST in prison: 2017 (or most recent) - 2021 (or most recent)

2017

2021





Final reflections..

Issues Delay in introduction



What to do?

Speed up the process- COVID19 example

Low coverage/Lack of implementation



Set up political and practical conditions for actual implementation of interventions (i.e. models of care, training, etc.)

Scarce evidence and lack of comparable data



Improve research and monitoring with use of comparable tools



https://www.emcdda.europa.eu/publications/ insights/prison-and-drugs-in-europe_en



Thank you!

linda.montanari@emcdda.europa.eu

